Compare LMAT & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LMAT | ADPT |
|---|---|---|
| Founded | 1983 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.7B |
| IPO Year | 2006 | 2019 |
| Metric | LMAT | ADPT |
|---|---|---|
| Price | $94.30 | $20.70 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 9 |
| Target Price | ★ $105.80 | $17.78 |
| AVG Volume (30 Days) | 292.9K | ★ 3.4M |
| Earning Date | 05-05-2026 | 05-05-2026 |
| Dividend Yield | ★ 0.93% | N/A |
| EPS Growth | 30.57 | ★ 63.89 |
| EPS | ★ 0.68 | N/A |
| Revenue | $249,602,000.00 | ★ $276,976,000.00 |
| Revenue This Year | $14.21 | $3.98 |
| Revenue Next Year | $8.88 | $22.72 |
| P/E Ratio | $138.13 | ★ N/A |
| Revenue Growth | 13.53 | ★ 54.77 |
| 52 Week Low | $79.01 | $9.96 |
| 52 Week High | $118.01 | $20.76 |
| Indicator | LMAT | ADPT |
|---|---|---|
| Relative Strength Index (RSI) | 47.80 | 71.02 |
| Support Level | $82.26 | $15.08 |
| Resistance Level | $97.83 | N/A |
| Average True Range (ATR) | 3.02 | 1.33 |
| MACD | 0.63 | 0.28 |
| Stochastic Oscillator | 61.26 | 93.68 |
LeMaitre Vascular Inc is a provider of medical devices and human tissue cryopreservation services mainly used in the treatment of peripheral vascular disease, end-stage renal disease, and cardiovascular disease. The company develops, manufactures, and markets vascular devices to address the needs of vascular surgeons and, to a lesser extent, other specialties such as cardiac surgeons, general surgeons, and neurosurgeons. Its diversified portfolio consists of branded products used in arteries and veins that are well known to vascular surgeons. It operates across the Americas, Europe, the Middle East and Africa, and Asia Pacific, with the majority of its revenue generated from the Americas.
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.